PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1987 June; 80(6): 368–373.
PMCID: PMC1290858

Graft-versus-host disease: a review.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Trentin JJ, Judd KP. Prevention of acute graft-versus-host (GVH) mortality with spleen-absorbed antithymocyte globulin (ATG). Transplant Proc. 1973 Mar;5(1):865–868. [PubMed]
  • THOMAS ED, HERMAN EC, Jr, GREENOUGH WB, 3rd, HAGER EB, CANNON JH, SAHLER OD, FERREBEE JW. Irradiation and marrow infusion in leukemia. Observations in five patients with acute leukemia treated by whole-body exposures of 1,400 to 2,000 roentgens and infusions of marrow. Arch Intern Med. 1961 Jun;107:829–845. [PubMed]
  • THOMAS ED, LOCHTE HL, Jr, CANNON JH, SAHLER OD, FERREBEE JW. Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest. 1959 Oct;38:1709–1716. [PMC free article] [PubMed]
  • McGOVERN JJ, Jr, RUSSELL PS, ATKINS L, WEBSTER EW. Treatment of terminal leukemic relapse by total-body irradiation and intravenous infusion of stored autologous bone marrow obtained during remission. N Engl J Med. 1959 Apr 2;260(14):675–683. [PubMed]
  • Bach FH, van Rood JJ. The major histocompatibility complex--genetics and biology. (First of three parts). N Engl J Med. 1976 Oct 7;295(15):806–813. [PubMed]
  • Storb R, Epstein RB, Graham TC, Thomas ED. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation. 1970 Mar;9(3):240–246. [PubMed]
  • Powles RL, Barrett AJ, Clink H, Kay HE, Sloane J, McElwain TJ. Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet. 1978 Dec 23;2(8104-5):1327–1331. [PubMed]
  • Prentice HG, Blacklock HA, Janossy G, Bradstock KF, Skeggs D, Goldstein G, Hoffbrand AV. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet. 1982 Mar 27;1(8274):700–703. [PubMed]
  • Gluckman E, Berger R, Dutreix J. Bone marrow transplantation for Fanconi anemia. Semin Hematol. 1984 Jan;21(1):20–26. [PubMed]
  • Lampert IA, Janossy G, Suitters AJ, Bofill M, Palmer S, Gordon-Smith E, Prentice HG, Thomas JA. Immunological analysis of the skin in graft versus host disease. Clin Exp Immunol. 1982 Oct;50(1):123–131. [PubMed]
  • Witherspoon RP, Lum LG, Storb R. Immunologic reconstitution after human marrow grafting. Semin Hematol. 1984 Jan;21(1):2–10. [PubMed]
  • Seto F. Enlargement and immune activity of chick embryo host spleen associated with transfer of B-haplotype-matched donor lymphoid cells. Exp Hematol. 1984 Jan;12(1):53–59. [PubMed]
  • Gluckman E, Devergie A, Sohier J, Saurat JH. Graft-versus-host disease in recipients of syngeneic bone marrow. Lancet. 1980 Feb 2;1(8162):253–254. [PubMed]
  • Müller-Ruchholtz W, Müller-Hermelink HK, Wottge HU. Induction of lasting hemopoietic chimerism in a xenogeneic (rat to mouse) model. Transplant Proc. 1979 Mar;11(1):517–521. [PubMed]
  • Kay H, Lumley H, Clink HM, Powles RL. Ratio of blood and marrow-derived cells in bone marrow transplantation. J Clin Pathol. 1982 May;35(5):492–495. [PMC free article] [PubMed]
  • Jones JM, Wilson R, Bealmear PM. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res. 1971 Mar;45(3):577–588. [PubMed]
  • van Bekkum DW, Knaan S. Role of bacterial microflora in development of intestinal lesions from graft-versus-host reaction. J Natl Cancer Inst. 1977 Mar;58(3):787–790. [PubMed]
  • Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J, Doney K, Hansen JA, Mason M, Sanders JE, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med. 1983 Feb 10;308(6):302–307. [PubMed]
  • Deeg HJ, Storb R. Graft-versus-host disease: pathophysiological and clinical aspects. Annu Rev Med. 1984;35:11–24. [PubMed]
  • Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, Doney KC, Buckner CD, Clift RA, Witherspoon RP, Appelbaum FA, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983 Apr;98(4):461–466. [PubMed]
  • Kendra J, Barrett AJ, Lucas C, Joshi R, Joss V, Desai M, Halil O, Rogers TR, Hobbs JR, Hugh-Jones K. Response of graft versus host disease to high doses of methyl prednisolone. Clin Lab Haematol. 1981;3(1):19–26. [PubMed]
  • Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, Schubert MM, Atkinson K, Thomas ED. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981 Feb;57(2):267–276. [PubMed]
  • Ramsay NK, Kersey JH, Robison LL, McGlave PB, Woods WG, Krivit W, Kim TH, Goldman AI, Nesbit ME., Jr A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med. 1982 Feb 18;306(7):392–397. [PubMed]
  • Barrett AJ, Kendra JR, Lucas CF, Joss DV, Joshi R, Pendharkar P, Hugh-Jones K. Cyclosporin A as prophylaxis against graft-versus-host disease in 36 patients. Br Med J (Clin Res Ed) 1982 Jul 17;285(6336):162–166. [PMC free article] [PubMed]
  • Rodt H, Kolb HJ, Netzel B, Haas RJ, Wilms K, Götze CB, Link H, Thierfelder S. Effect of anti-T-cell globulin on GVHD in leukemic patients treated with BMT. Transplant Proc. 1981 Mar;13(1 Pt 1):257–261. [PubMed]
  • Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Dupont B, Good RA, O'Reilly RJ. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet. 1981 Aug 15;2(8242):327–331. [PubMed]
  • Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, Waldmann H. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983 Oct;62(4):873–882. [PubMed]
  • Treleaven JG, Gibson FM, Ugelstad J, Rembaum A, Philip T, Caine GD, Kemshead JT. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet. 1984 Jan 14;1(8368):70–73. [PubMed]
  • Filipovich AH, McGlave PB, Ramsay NK, Goldstein G, Warkentin PI, Kesey JH. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet. 1982 Jun 5;1(8284):1266–1269. [PubMed]
  • Bozdech MJ, Sondel PM, Trigg ME, Longo W, Kohler PC, Flynn B, Billing R, Anderson SA, Hank JA, Hong R. Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection. Exp Hematol. 1985 Dec;13(11):1201–1210. [PubMed]
  • de Witte T, Raymakers R, Plas A, Koekman E, Wessels H, Haanen C. Bone marrow repopulation capacity after transplantation of lymphocyte-depleted allogeneic bone marrow using counterflow centrifugation. Transplantation. 1984 Feb;37(2):151–155. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press